Tianyu Corporation (300702.SZ): Budesonide API passes CDE review

Chinastocks APP News, Tianyu shares (300702.SZ) announced that the company's Buplixtan raw material has recently passed the review of the Drug Evaluation Center (CDE) of the National Medical Products Administration. This drug is used for the adjuvant treatment of partial seizures, especially for patients who do not respond well to other anti-seizure medications.